The lawsuits filed on behalf of cancer patients who allegedly experienced
permanent hair loss following treatment with the chemotherapy drug Taxotere
are moving forward in a multidistrict litigation established in the U.S.
District Court, Eastern District of Louisiana. Initially, the MDL began
with 33 cases. In December, the number of cases was reported at 267. As
of January 18, 2017, there were 705 cases.
Taxotere is one of many chemotherapy agents on the market. Patients and
doctors often choose Taxotere because unlike other chemotherapy drugs,
Taxotere is generally administered once every three weeks as opposed to
once per week. Had users been informed of the potential risk of permanent
hair loss, they could have chosen a different treatment option. While
chemotherapy patients are well aware of the risk of temporarily losing
their hair, they believe that they will regrow their hair after chemotherapy
treatment is complete.
The rising number of lawsuits being filed indicates that many patients
may have experienced the adverse side effect of permanent hair loss after
taking Taxotere. In August, we published a
blog discussing Taxotere hair loss, pending lawsuits, and the failues of Sanofi-Aventis,
the manufacturer of Taxotere, in warning patients and medical professionals
about the risks associated with the drug.
If you or someone you love has experienced permanent hair loss or alopecia
after taking Taxotere, you may be entitled to compensation for your damages,
including the emotional injuries you sustained when you and your doctor
chose a drug you believed to be safe. Brett H. Oppenheimer, PLLC is currently
investigating these cases and can assist you in understanding your legal
rights and whether you may have a valid claim.
To discuss your case during a free consultation,
contact Brett today. Mr. Oppenheimer is a proven personal injury lawyer who has recovered
more than $100 million in compensation for clients across Louisville and
the state of Kentucky.